Nexxen Reports Results for the Fourth Quarter and Year Ended December 31, 2023
Achieved full year 2023 Contribution ex-TAC and Adjusted EBITDA above the midpoints of the Company’s guidance Grew programmatic revenue 9% […]
Amesite Announces Launch of Active Shooter Preparedness App with World Renowned Expert Chris Grollnek
DETROIT, March 06, 2024 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based […]
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss […]
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the […]
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company […]
23andMe Launches New Genetic Reports on Common Forms of Cancer
SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and […]
Ollie’s Bargain Outlet Holdings, Inc. Announces Fourth Quarter and Full-Year Fiscal 2023 Release Date and Conference Call Information
HARRISBURG, Pa., March 06, 2024 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) announced today that […]
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter – – Dose escalation of […]
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that treat […]
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
Generated Record Revenues with Robust 50% Year-over-Year Revenue Growth in Q4 2023; Generated Positive Quarterly Net Income Providing Full-Year 2024 Revenue […]
